VDAC1-NF-κB/p65-mediated S100A16 contributes to myocardial ischemia/reperfusion injury by regulating oxidative stress and inflammatory response via calmodulin/CaMKK2/AMPK pathway

IF 4.2 3区 医学 Q1 PHARMACOLOGY & PHARMACY European journal of pharmacology Pub Date : 2025-01-15 DOI:10.1016/j.ejphar.2024.177158
Congna Zi , Xian Ma , Maodong Zheng , Ying Zhu
{"title":"VDAC1-NF-κB/p65-mediated S100A16 contributes to myocardial ischemia/reperfusion injury by regulating oxidative stress and inflammatory response via calmodulin/CaMKK2/AMPK pathway","authors":"Congna Zi ,&nbsp;Xian Ma ,&nbsp;Maodong Zheng ,&nbsp;Ying Zhu","doi":"10.1016/j.ejphar.2024.177158","DOIUrl":null,"url":null,"abstract":"<div><div>Myocardial injury triggers intense inflammatory reactions and oxidative stress responses. S100 calcium-binding protein A16 (S100A16), a multi-functional calcium (Ca<sup>2+</sup>)-binding protein, participates in inflammatory responses and contributes to ischemia/reperfusion (I/R) injury. Nevertheless, the precise mechanism by which S100A16 operates in myocardial I/R injury remains uncertain. Cardiac I/R injury was produced by ligation/release of the left anterior descending artery, and mouse cardiac cells were subjected to hypoxia/reoxygenation (H/R) to determine the biological effects <em>in vitro</em>. We demonstrated that S100A16 was upregulated in the ischemic hearts and cardiac cells after I/R and H/R injury. Adenovirus-mediated S100A16 inhibition led to a considerable improvement in cardiac function with a reduced infarct size, accompanied by a reduction in cardiomyocyte apoptosis. Similar effects of S100A16 inhibition on inflammation and reactive oxygen species (ROS) production were observed in cultured cardiomyocytes. Importantly, we showed that I/R and H/R treatment upregulated the expression of voltage-dependent anion channel 1 (VDAC1), which subsequently activated NF-κB/p65 to facilitate the binding of NF-κB/p65 to the S100A16 promoter, thereby activating the transcription and expression of S100A16. Mechanically, S100A16 responded to increasing Ca<sup>2+</sup> and interacted with calmodulin (CaM) to regulate the activation of calcium/calmodulin-dependent protein kinase 2 (CAMKK2)/AMPK pathway. In conclusion, VDAC1 sustained the NF-κB p65 pathway activation to elicit increased S100A16 expression, contributing to myocardial damage and heart failure post-I/R via the CaM/CaMKK2/AMPK pathway. This study revealed a crucial role of the VDAC1-S100A16 axis in the process of myocardial I/R injury, providing novel molecular targets for the treatment of cardiac conditions associated with I/R injury.</div></div>","PeriodicalId":12004,"journal":{"name":"European journal of pharmacology","volume":"987 ","pages":"Article 177158"},"PeriodicalIF":4.2000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0014299924008483","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Myocardial injury triggers intense inflammatory reactions and oxidative stress responses. S100 calcium-binding protein A16 (S100A16), a multi-functional calcium (Ca2+)-binding protein, participates in inflammatory responses and contributes to ischemia/reperfusion (I/R) injury. Nevertheless, the precise mechanism by which S100A16 operates in myocardial I/R injury remains uncertain. Cardiac I/R injury was produced by ligation/release of the left anterior descending artery, and mouse cardiac cells were subjected to hypoxia/reoxygenation (H/R) to determine the biological effects in vitro. We demonstrated that S100A16 was upregulated in the ischemic hearts and cardiac cells after I/R and H/R injury. Adenovirus-mediated S100A16 inhibition led to a considerable improvement in cardiac function with a reduced infarct size, accompanied by a reduction in cardiomyocyte apoptosis. Similar effects of S100A16 inhibition on inflammation and reactive oxygen species (ROS) production were observed in cultured cardiomyocytes. Importantly, we showed that I/R and H/R treatment upregulated the expression of voltage-dependent anion channel 1 (VDAC1), which subsequently activated NF-κB/p65 to facilitate the binding of NF-κB/p65 to the S100A16 promoter, thereby activating the transcription and expression of S100A16. Mechanically, S100A16 responded to increasing Ca2+ and interacted with calmodulin (CaM) to regulate the activation of calcium/calmodulin-dependent protein kinase 2 (CAMKK2)/AMPK pathway. In conclusion, VDAC1 sustained the NF-κB p65 pathway activation to elicit increased S100A16 expression, contributing to myocardial damage and heart failure post-I/R via the CaM/CaMKK2/AMPK pathway. This study revealed a crucial role of the VDAC1-S100A16 axis in the process of myocardial I/R injury, providing novel molecular targets for the treatment of cardiac conditions associated with I/R injury.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
VDAC1-NF-κB/p65介导的S100A16通过Calmodulin/CaMKK2/AMPK通路调节氧化应激和炎症反应,参与心肌缺血/再灌注损伤。
心肌损伤引发强烈的炎症反应和氧化应激反应。S100钙结合蛋白A16 (S100A16)是一种多功能钙(Ca2+)结合蛋白,参与炎症反应,参与缺血/再灌注(I/R)损伤。然而,S100A16在心肌I/R损伤中的确切作用机制尚不清楚。通过结扎/释放左前降支造成心脏I/R损伤,并对小鼠心肌细胞进行缺氧/再氧化(H/R),以确定体外生物学效应。我们发现,缺血心脏和心肌细胞在I/R和H/R损伤后,S100A16表达上调。腺病毒介导的S100A16抑制导致心肌功能的显著改善,梗死面积减少,同时心肌细胞凋亡减少。在培养的心肌细胞中,S100A16对炎症和活性氧(ROS)产生的抑制作用也类似。重要的是,我们发现I/R和H/R处理上调了电压依赖性阴离子通道1 (VDAC1)的表达,VDAC1随后激活NF-κB/p65,促进NF-κB/p65与S100A16启动子的结合,从而激活S100A16的转录和表达。机械上,S100A16响应Ca2+的增加,并与钙调素(CaM)相互作用,调节钙/钙调素依赖性蛋白激酶2 (CAMKK2)/AMPK途径的激活。综上所述,VDAC1维持NF-κB p65通路激活,引发S100A16表达增加,通过CaM/CaMKK2/AMPK通路参与i /R后心肌损伤和心力衰竭。本研究揭示了VDAC1-S100A16轴在心肌I/R损伤过程中的重要作用,为I/R损伤相关心脏疾病的治疗提供了新的分子靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
文献相关原料
公司名称
产品信息
索莱宝
ROS Detection Kit
索莱宝
DAB reagent
索莱宝
Master Mix SYBR Green system
索莱宝
MEM medium
来源期刊
CiteScore
9.00
自引率
0.00%
发文量
572
审稿时长
34 days
期刊介绍: The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems. The scope includes: Behavioural pharmacology Neuropharmacology and analgesia Cardiovascular pharmacology Pulmonary, gastrointestinal and urogenital pharmacology Endocrine pharmacology Immunopharmacology and inflammation Molecular and cellular pharmacology Regenerative pharmacology Biologicals and biotherapeutics Translational pharmacology Nutriceutical pharmacology.
期刊最新文献
The diabetes medication Canagliflozin attenuates alcoholic liver disease by reducing hepatic lipid accumulation via SIRT1-AMPK-mTORC1 signaling pathway. Synergistic combination of doxorubicin with fisetin for the treatment of lymphoma Disulfiram alleviates immune-mediated liver injury by inhibiting pyroptosis in hepatocytes through the NF-κB pathway Hydrogen-rich water ameliorates imiquimod-induced psoriasis-like skin lesions and regulates macrophage polarization in dyslipidemic ApoE-deficient mice Agmatine mitigates hyperexcitability of ventral tegmental area dopaminergic neurons in prenatally stressed male offspring
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1